July 2013 ta report jb update 13.8.13.xls

QVH NICE Technology Appraisal ReportReport generated from local_bnf provided by FormularyComplete (www.pharmpress.com). Accessed 16 05 2013 updated 13 08 2013
Items/TAs marked as non-formulary are not relevant to the services provided by the Queen Victoria Hospital NHS Foundation Trust
TA Number Medicine TitleFormulary StatusComments
Formulary for NICE indications as recommended by consultant
Consultant rheumatologist only. As per NICE guidance.
Initiation by Consultant Cardiologist / Physician only
QVH NICE Technology Appraisal Report
Initiation by Consultant Cardiologist / Physician only
Formulary for NICE indications as recommended by consultant
NICE TA260 not relevant to QVH. Only for LD or rectus muscle spasm (post trauma flap), messenteric hypertrophy, induction of ptosis&nbsp;and hyperhidrosis. Multiple use for eye clinic and facial
Formulary for NICE indications as recommended by Consultant
Only as per NICE guidance but not relevant to QVH
Formulary for NICE indications as recommended by consultant
Not relevant to QVH. Patients would be referred for this treatment
Formulary for NICE indications but not relevant for QVH.
NICE TA244 not relevant to QVH. Only as per NICE guidance as part
Not relevant to QVH. Patients would be referred for this treatment
QVH NICE Technology Appraisal Report
Consultant rheumatologist only. As per NICE guidance.
Consultant rheumatologist only. As per NICE guidance.
Not relevant to QVH. Patients would be referred for this treatment
Consultant rheumatologist only. As per NICE guidance.
Naftidrofuryl oxalate for treatment of intermittent claudication in people
with peripheral arterial disease as per NICE guidance.
NICE TA 223 not relevant to QVH. Only for osteonecrosis of the jaw -
Consultant rheumatologist only. As per NICE guidance.QVH NICE Technology Appraisal Report
NICE TA212 not relevant to QVH. Ophthalmology only topical or intra-ocular injection. Only available as 10mg in 0.4ml. UNLICENSED.<br />
Not relevant at QVH for NICE indication.
NICE TA211 not relevant to QVH. For continuation treatment only.
Only as per NICE as recommended by consultant physician
Patients would be referred for this treatment elsewhere
Consultant rheumatologist only. As per NICE guidance
Consultant rheumatologist only. As per NICE guidance.
Not relevant to QVH. Patients would be referred for this treatment
Patients would be referred for this treatment elsewhere
Not relevant to QVH. Patients would be referred for this treatment
Consultant rheumatologist only. As per NICE guidance
Consultant rheumatologist only. As per NICE guidance.
Not relevant to QVH. Patients would be referred for this treatment
NICE TA188 not relevant to QVH. Burns only
Patient transferred to another provider if this treatment required
Consultant rheumatologist only. As per NICE guidance
Consultant rheumatologist only. As per NICE guidance
QVH NICE Technology Appraisal Report
Not relevant to QVH. Patients would be referred for this treatment
Consultant dermatologist only. Women of child-bearing potential must
Not relevant to QVH. Patients would be referred for this treatment
NICE not relevant to QVH. In PEP pack as Truvada
Formulary for NICE indications as recommended by consultant
Only as recommended by consultant rheumatologist as per NICE
guidance where allopurinol is not tolerated or is contraindicated.
Patient transferred to another provider if this treatment required
1st Line bisphosphonate- see NICE guidance. Use WEEKLY dosage
2nd Line bisphosphonate. Use WEEKLY dosage
Only if bisphosphonates contraindicated or not tolerated AND T-score,
age and number of independent clinical risk factors meet NICE criteria
Only as per NICE if alendronate cannot be used.QVH NICE Technology Appraisal Report
Only for SECONDARY prevention of osteoporotic fragility fractures in
postmenopausal women if bisphosphonates not tolerated or
contraindicated and other NICE criteria met
Only as per NICE as recommended by consultant physician
1st Line bisphosphonate- see NICE guidance. Use WEEKLY dosage
2nd Line bisphosphonate. Use WEEKLY dosage
Only if bisphosphonates contraindicated or not tolerated AND T-score,
age and number of independent clinical risk factors meet NICE criteria
Only as per NICE if alendronate cannot be used.
Only for SECONDARY prevention of osteoporotic fragility fractures in
postmenopausal women if bisphosphonates not tolerated or
contraindicated and other NICE criteria met
Formulary for NICE indications as recommended by consultant
Only as per NICE guidance but not relevant to QVH.
Consultant rheumatologist only. As per NICE guidance
Patients would be referred for this treatment elsewhere
Consultant rheumatologist only. As per NICE guidance
Consultant rheumatologist only. As per NICE guidance.
Patient transferred to another provider if this treatment required
Not relevant to QVH. Patients would be referred for this treatment
Not relevant to QVH. Patients would be referred for this treatment
Patients would be referred for this treatment elsewhere
QVH NICE Technology Appraisal Report
Consultant rheumatologist only. As per NICE guidance
Consultant rheumatologist only. As per NICE guidance.
Consultant rheumatologist only. As per NICE guidance.
Consultant dermatologist only as per NICE guidance and for licensed indications. Also for resistant cases of erosive lichen planus for Maxfax
Consultant dermatologist only as per NICE guidance
QVH NICE Technology Appraisal Report
NICE TA not relevant to QVH. Consultant ophthalmologist only. Injection (Roferon) -UNLICENSED use. 1million units/ml eyedrops, not routinely stocked must be ordered for individual patients and is only made every 4 weeks - UNLICENSED. PCT funding approval needed
Not relevant to QVH. Patients would be referred for this treatment
NICE TA64 not relevant to QVH. Burns only
NICE TA20 not relevant to QVH. Only if meets NICE guidance for treatment of amyotrophic lateral sclerosis form of motor neurone

management | qof A total of eight points are available to practices for the correct management and treatment of obesity. Dr PAul lAmbDen explainsObesity is rapidly becoming the United Kingdom’s biggest health problem with associated deaths estimated at between 10-30,000 a year from obesity alone. Nearly two-thirds (70 per cent) of men and 63 per cent of women are over-weight or obese and it